AI Article Synopsis
- Immunotherapy has revolutionized cancer treatment, but its effectiveness is mostly seen in patients with specific types of colorectal cancer (dMMR and MSI-H).
- Understanding the tumor immune microenvironment (TIME) and different immune-related subtypes is crucial for enhancing the effectiveness of immunotherapy.
- By identifying these immune subtypes, researchers hope to clarify how they influence responses to treatment and improve strategies for managing colorectal cancer.
Article Abstract
Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590894 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1259461 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!